<DOC>
	<DOCNO>NCT01786655</DOCNO>
	<brief_summary>The primary aim Phase 1 study evaluate systemic safety novel prolonged-duration local anesthetic , Neosaxitoxin ( NeoSTX ) , give subcutaneous injection combination commonly use local anesthetic , bupivacaine , epinephrine . The investigator hypothesize `` minimal adverse effect threshold '' NeoSTX dose subcutaneous administration combination bupivacaine 0.2 % epinephrine 5mcg/ml respectively , define awake , young adult healthy volunteer subject . At time , pharmacokinetics NeoSTX deliver subcutaneously determine .</brief_summary>
	<brief_title>Safety Study Long-Acting Local Anesthetic</brief_title>
	<detailed_description>Currently available amino amide local anesthetic ( e.g . bupivacaine , levobupivacaine , ropivacaine ) reliably provide analgesia beyond roughly 8 hour follow subcutaneous infiltration . In addition , cause systemic toxicity seizure , arrhythmia , cardiac arrest , well local tissue toxicity muscle , cartilage nerve . Therefore , need safe local anesthetic provide long duration analgesia low systemic local tissue toxicity . The investigator team previously report tetrodotoxin , saxitoxin , NeoSTX could produce prolonged sensory blockade ( numbness ) motor blockade ( weakness ) follow injection near sciatic nerve rat . In study , combine site 1 toxin either bupivacaine epinephrine dramatically improve efficacy ( duration sensory blockade ) reduce systemic toxicity . NeoSTX potent member STX series identify date . In preliminary study , investigator University Chile , Santiago , small biotech company , Proteus S.A , develop bioreactor process produce clinical grade NeoSTX efficiently , excellent purity , stability , sterility non-pyrogenicity . A series preclinical safety toxicologic study mice , rat , sheep perform CHB Toxikon , Inc . In proposal , investigator plan conduct Phase I study perform Investigator-Initiated FDA IND establish systemic local safety escalate dos NeoSTX via sub-cutaneous infiltration healthy awake young adult male human volunteer subject . The primary aim Phase 1 study evaluate systemic safety novel prolonged-duration local anesthetic , neosaxitoxin ( NeoSTX ) , give subcutaneous injection , either alone combination commonly use local anesthetic , bupivacaine , epinephrine . The hypothesis , use adverse event endpoint , `` minimal adverse effect threshold '' NeoSTX dose subcutaneous administration combination bupivacaine 0.2 % epinephrine 5mcg/ml respectively , define awake , young adult healthy volunteer subject . In double blind fashion , subject receive two injection simultaneously 3 cm x 3cm square area skin posterior aspect low leg ( calf ) , one side . Each subject receive one injection bupivacaine 0.2 % alone one side . On side , receive one 4 possible solution : ( 1 ) saline placebo , ( 2 ) NeoSTX saline ( 3 ) NeoSTX combination bupivacaine ( 4 ) NeoSTX combination bupivacaine 0.2 % epinephrine 5mcg/ml . In dose group , one injection involve placebo . Prior dose increase , safety review confirmation stop rule reach . Specific Aims 1 . Measure dose dependence FDA-AEs SD-AEs NeoSTX saline ; 2 . Measure dose dependence FDA-AEs SD-AEs NeoSTX bupivacaine 0.2 % ; 3 . Measure dose dependence FDA-AEs SD-AEs NeoSTX bupivacaine 0.2 % epinephrine 5mcg/ml ; 4 . Measure serum urine concentration NeoSTX follow injection NeoSTX alone bupivacaine 0.2 % without epinephrine ; correlate serum concentration `` Systemic Effects '' ; 5 . Evaluate skin integrity potential local reaction ( edema , numbness , paresthesia , erythema ) treat limbs receive NeoSTX-saline , NeoSTX-bupivacaine , NeoSTX-bupivacaine-epinephrine plain bupivacaine . 6 . Using QST , establish dependence sensory blockade intensity duration NeoSTX dose presence absence bupivacaine epinephrine ;</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Anesthetics , Local</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Neosaxitoxin</mesh_term>
	<criteria>1 . Healthy adult male age 1835 2 . ASA physical status 1 2 3 . English Spanish speaker 4 . Must able come Boston Children 's Hospital 24hour stay able willing attend 510 study visit 5 . Must able provide inform consent 6 . Must able understand perform procedure study include selfreporting symptom score 1 . ASA physical status 3 great 2 . Cognitively challenged inability understand selfreport measure give inform consent 3 . Significant cardiovascular , respiratory , neuromuscular disease systemic illness ( e ) 4 . No know suspected allergy neosaxitoxin , bupivacaine , local anesthetic 5 . Subjects may pain control medication , medication would alter pain tolerance 6 . Subjects may medication would alter cognition 7 . Subjects may acute chronic pain condition require ongoing treatment limit daily activity 8 . No alcohol illicit drug abuse 9 . No current smoker</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>local anesthetic</keyword>
	<keyword>neosaxitoxin</keyword>
	<keyword>neoSTX</keyword>
	<keyword>bupivacaine</keyword>
	<keyword>safety</keyword>
	<keyword>phase 1</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>